Insider · CIK 0001376043

Coughlin Timothy

Reports to the SEC for 6 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001376043

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-12	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$26.52	+$265K	66,250
2026-06-12	TVTXTravere Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−10K sh	—	—	0
2026-06-12	TVTXTravere Therapeutics, Inc.S Sale	Director	SSale	−10K sh	$50.07	−$501K	56,250
2026-06-09	VIRVir Biotechnology, Inc.A Award	Director	AAward	+8,000 sh	—	—	16,000
2026-06-09	VIRVir Biotechnology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+16K sh	—	—	16,000
2026-06-09	VIRVir Biotechnology, Inc.A Award	Director	AAward	+8,000 sh	—	—	8,000
2026-06-09	VIRVir Biotechnology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+16K sh	—	—	16,000
2026-06-03	ADCTADC Therapeutics SAF Tax Payment	Director	FTax Payment	−12.6K sh	$3.08	−$38.8K	72,400
2026-06-01	ADCTADC Therapeutics SAA Award	Director	AAward	+45K sh	—	—	85,000
2026-05-19	TVTXTravere Therapeutics, Inc. · Stock option (right to buy)A Award	Director	AAward	+12K sh	—	—	12,000
2026-05-19	TVTXTravere Therapeutics, Inc.A Award	Director	AAward	+4,000 sh	—	—	56,250
2026-05-15	TVTXTravere Therapeutics, Inc.S Sale	Director	SSale	−3,250 sh	$43.49	−$141K	52,250
2026-05-11	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+50K sh	—	—	50,000
2025-10-31	TVTXTravere Therapeutics, Inc. · Director stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−10K sh	—	—	0
2025-10-31	TVTXTravere Therapeutics, Inc. · Director stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−8,000 sh	—	—	0
2025-10-31	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+8,000 sh	$16.33	+$131K	63,500
2025-10-31	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$17.44	+$174K	73,500
2025-10-31	TVTXTravere Therapeutics, Inc.S Sale	Director	SSale	−18K sh	$35.03	−$631K	55,500
2025-06-03	ADCTADC Therapeutics SAA Award	Director	AAward	+40K sh	—	—	40,000
2025-06-03	ADCTADC Therapeutics SA · Stock Options (Right to Buy)A Award	Director	AAward	+80K sh	—	—	80,000
2025-05-15	TVTXTravere Therapeutics, Inc. · Stock option (right to buy)A Award	Director	AAward	+19.5K sh	—	—	19,500
2025-05-15	TVTXTravere Therapeutics, Inc.A Award	Director	AAward	+6,500 sh	—	—	55,500
2025-05-01	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+50K sh	—	—	50,000
2024-06-07	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2024-05-30	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+50K sh	$1.75	+$87.5K	56,000
2024-05-22	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+24K sh	—	—	24,000
2024-05-08	TVTXTravere Therapeutics, Inc.A Award	Director	AAward	+6,500 sh	—	—	49,000
2024-05-08	TVTXTravere Therapeutics, Inc. · Stock option (right to buy)A Award	Director	AAward	+19.5K sh	—	—	19,500
2023-06-06	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2023-05-17	TVTXTravere Therapeutics, Inc. · Stock option (right to buy)A Award	Director	AAward	+13.5K sh	—	—	13,500
2023-05-17	TVTXTravere Therapeutics, Inc.A Award	Director	AAward	+4,500 sh	—	—	42,500
2023-05-17	ATYRaTYR PHARMA INCG Gift	Director	GGift	−6,000 sh	—	—	0
2023-05-17	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+12K sh	—	—	12,000
2023-05-17	ATYRaTYR PHARMA INCG Gift	Director	GGift	+6,000 sh	—	—	6,000
2023-04-26	ATYRaTYR PHARMA INC · Restricted Stock UnitM Exercise/Conversion	Director	MExercise/Conversion	−6,000 sh	—	—	0
2023-04-26	ATYRaTYR PHARMA INCM Exercise/Conversion	Director	MExercise/Conversion	+6,000 sh	—	—	6,000
2022-06-09	FATEFATE THERAPEUTICS INCA Award	Director	AAward	+8,650 sh	—	—	9,892
2022-06-09	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+11.9K sh	—	—	11,893
2022-06-03	FATEFATE THERAPEUTICS INCS Sale	Director	SSale	−1,439 sh	$22.81	−$32.8K	57,632
2022-05-11	TVTXTravere Therapeutics, Inc.A Award	Director	AAward	+3,000 sh	—	—	38,000
2022-05-11	TVTXTravere Therapeutics, Inc. · Stock option (right to buy)A Award	Director	AAward	+9,000 sh	—	—	9,000
2022-04-26	ATYRaTYR PHARMA INC · Restricted Stock UnitsA Award	Director	AAward	+6,000 sh	—	—	6,000
2021-06-02	FATEFATE THERAPEUTICS INCA Award	Director	AAward	+2,681 sh	—	—	59,071
2021-06-02	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+4,334 sh	—	—	4,334
2021-05-14	TVTXTravere Therapeutics, Inc. · Stock option (right to buy)A Award	Director	AAward	+9,000 sh	—	—	9,000
2021-05-14	TVTXTravere Therapeutics, Inc.A Award	Director	AAward	+3,000 sh	—	—	35,000
2021-04-28	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+1,428 sh	—	—	1,428
2020-05-15	TVTXTravere Therapeutics, Inc.A Award	Director	AAward	+3,000 sh	—	—	32,000
2020-05-15	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)A Award	Director	AAward	+9,000 sh	—	—	9,000
2020-05-06	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+1,428 sh	—	—	1,428

Recent filings

Accepted (ET)
Jun 164
Coughlin Timothy0001376043-26-000010
SEC(opens sec.gov)
Jun 104
Coughlin Timothy0001628280-26-042326
SEC(opens sec.gov)
Jun 34
Coughlin Timothy0001628280-26-040487
SEC(opens sec.gov)
May 214
Coughlin Timothy0001376043-26-000006
SEC(opens sec.gov)
May 194
Coughlin Timothy0001376043-26-000005
SEC(opens sec.gov)
May 134
Coughlin Timothy0001376043-26-000003
SEC(opens sec.gov)
Nov 44
Coughlin Timothy0001376043-25-000004
SEC(opens sec.gov)
Jun 54
COUGHLIN TIMOTHY0001628280-25-029742
SEC(opens sec.gov)

Companies

Address

C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DR., SUITE 300

SAN DIEGO, CA, 92130